Advertisement
Advances in Chronic Kidney Disease
NKF
Advanced SearchSave search
Article| Volume 21, ISSUE 4, P344-348, July 01, 2014

Research in the CKD Clinic: Highs and Lows

  • Emily Decker
    Affiliations
    Division of Renal Diseases and Hypertension, University of Colorado–Denver, Aurora, CO; and Division of Renal Diseases and Hypertension, University of Colorado–Denver, Aurora, CO; Denver Health Medical Center, Denver, CO
    Search for articles by this author
  • Jessica Kendrick
    Correspondence
    Address correspondence to Jessica Kendrick, MD, Division of Renal Diseases and Hypertension, University of Colorado–Denver, Denver Health Medical Center, 660 Bannock Street, Mail Code 4000, Denver, CO 80204.
    Affiliations
    Division of Renal Diseases and Hypertension, University of Colorado–Denver, Aurora, CO; and Division of Renal Diseases and Hypertension, University of Colorado–Denver, Aurora, CO; Denver Health Medical Center, Denver, CO
    Search for articles by this author
DOI:https://doi.org/10.1053/j.ackd.2014.02.012
Research in the CKD Clinic: Highs and Lows
Previous ArticleThe Nephrology Interdisciplinary Team: An Education Synergism
Next ArticleMedication Pitfalls in the CKD Clinic: Case Presentations
      Despite rates of CKD continuing to increase, the current evidence base used to guide CKD management is smaller than that for many other chronic diseases. Clinical investigators face multiple barriers to conducting research in patients with CKD. CKD patients have multiple comorbidities that make them a risky intervention target; thus, they are often excluded from trials. The lack of approved surrogate endpoints for kidney disease progression makes testing therapies to slow progression very challenging and expensive. Patients with CKD have higher rates of disability and lower educational status than the general population, which further complicates their participation in clinical trials. Despite these barriers, it is imperative that scientific progress be made in this patient population. Increasing education and information regarding CKD clinical trials through brochures and public awareness campaigns may increase trial participation. The U.S. Food and Drug Administration needs to approve the new definition of glomerular filtration rate decline because this will result in a decrease in the cost of clinical trials and make industry more likely to invest in trials in patients with CKD. Successful research in this patient population is possible, but it requires collaboration among investigators, health-care providers, patients, industry, and the National Institutes of Health.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Coresh J.
        • Selvin E.
        • Stevens L.A.
        • et al.
        Prevalence of chronic kidney disease in the United States.
        J Am Med Assoc. 2007; 298: 2038-2047
        View in Article
        • Go A.S.
        • Chertow G.M.
        • Fan D.
        • et al.
        Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
        N Engl J Med. 2004; 351: 1296-1305
        View in Article
        • James M.T.
        • Hemmelgarn B.R.
        • Tonelli M.
        Early recognition and prevention of chronic kidney disease.
        Lancet. 2010; 375: 1296-1309
        View in Article

      4. National Institutes of Health. Available at: http://clinicaltrials.gov/ct2/search/advanced. Accessed August 26, 2013.

        View in Article
        • Stevens L.A.
        • Levin A.
        Translating research findings of chronic kidney disease management to clinical practice: challenges and opportunities.
        Adv Ren Replace Ther. 2004; 11: 66-75
        View in Article
        • Charytan D.
        • Kuntz R.E.
        The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease.
        Kidney Int. 2006; 70: 2021-2030
        View in Article
        • Trespalacios F.C.
        • Taylor A.J.
        • Agodoa L.Y.
        • Abbott K.C.
        Incident acute coronary syndromes in chronic dialysis patients in the United States.
        Kidney Int. 2002; 62: 1799-1805
        View in Article
        • Frank G.
        Current challenges in clinical trial patient recruitment and enrollment.
        SoCRA Source. 2004; : 30-38
        View in Article
        • English R.A.
        • Lebovitz Y.
        • Giffin R.B.
        Challenges in clinical research.
        in: Briere R. Transforming Clinical Research in the United States: Challenges and Opportunities. National Academies Press, Washington, DC2010: 19-36
        View in Article
        • Nelson K.
        • Garcia R.E.
        • Brown J.
        • et al.
        Do patient consent procedures affect participation rates in health services research?.
        Med Care. 2002; 40: 283-288
        View in Article
        • Klitzman R.
        From anonymity to “open doors”: IRB responses to tensions with researchers.
        BMC Res Notes. 2012; 5: 347-357
        View in Article

      12. National Institutes of Health. Available at: http://report.nih.gov/fundingfact/fundingfacts.aspx. Accessed August 5, 2013.

        View in Article
        • Emanuel E.
        • Schnipper L.
        • Kamin Y.
        • Levinson J.
        • Licher A.
        The costs of conducting clinical research.
        J Clin Oncol. 2003; 21: 4145-4150
        View in Article

      14. National Institutes of Health. Available at: http://report.nih.gov/success_rates/Success_ByIC_Details.cfm. Accessed August 14, 2013.

        View in Article

      15. National Institutes of Health. Available at: http://www.nih.gov/news/health/jun2013/nih-03.htm. Accessed August 14, 2013.

        View in Article

      16. National Institutes of Health. Available at: http://www2.niddk.nih.gov/Funding/Grants/FundingPolicy.htm. Accessed August 14, 2013.

        View in Article
        • Plantinga L.C.
        • Johansen K.L.
        • Schillinger D.
        • Powe N.R.
        Lower socioeconomic status and disability among US adults with chronic kidney disease, 1999-2008.
        Prev Chronic Dis. 2012; 9: 110052
        View in Article

      18. U.S. Census Bureau. Available at: http://www.census.gov/people/disability/. Accessed September 1, 2013.

        View in Article
        • Mason N.A.
        Polypharmacy and medication-related complications in the chronic kidney disease patient.
        Curr Opin Nephrol Hypertens. 2011; 20: 492-497
        View in Article

      20. U.S. Census Bureau. Available at: http://factfinder2.census.gov/faces/tableservices/jsf/pages/productview.xhtml?pid=ACS_12_1YR_CP02&prodType=table. Accessed September 1, 2013.

        View in Article
        • U.S. Renal Data System
        USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Diseases and End-Stage Renal Diseases in the United States.
        National Institutes of Health, Bethesda, MD2013
        View in Article

      22. ECRI Evidence Report. Patients' reasons for participation in clinical trials and effect of participation on patient outcomes. ECRI Health Technology Assessment Information Service. Plymouth Meeting, PA. April 2002, Issue No. 74.

        View in Article

      23. National Institutes of Health. Available at: http://officeofbudget.od.nih.gov/pdfs/spending_history/Basic%20and%20Applied%20FY%202002%20-%20FY%202014.pdf. Accessed January 16, 2014.

        View in Article
        • English R.A.
        • Lebovitz Y.
        • Giffin R.B.
        Building a robust clinical trials infrastructure.
        in: Briere R. Transforming Clinical Research in the United States: Challenges and Opportunities. National Academies Press, Washington, DC2010: 87-102
        View in Article

      Article Info

      Footnotes

      Support: The authors receive financial support from the National Institute of Diabetes and Digestive and Kidney Disease (Grant K23 DK087859 ).

      Identification

      DOI: https://doi.org/10.1053/j.ackd.2014.02.012

      Copyright

      © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX